Condition
Attention Deficit Hyperactivity Disorder Combined
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
80%
4 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 3 (3)
P 4 (1)
Trial Status
Completed3
Suspended1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05924594Phase 3Suspended
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
NCT05286762Phase 3Completed
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
NCT05631626Phase 3Completed
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
NCT04421248Phase 4RecruitingPrimary
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
NCT04378517Not ApplicableCompletedPrimary
Evaluating the Feasibility of FAM-SOTC Intervention for Families of Adolescents With ADHD: Pilot Study
Showing all 5 trials